Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant human interleukin-2

(ree-KOM-bih-nunt HYOO-mun in-ter-LOO-kin...)
A drug used to treat adults with melanoma or renal cell carcinoma (a type of kidney cancer) that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Recombinant human interleukin-2 is a form of interleukin-2 that is made in the laboratory. Recombinant human interleukin-2 increases the activity and growth of white blood cells called T lymphocytes and B lymphocytes, which may help the immune system kill cancer cells. Recombinant human interleukin-2 is a type of cytokine and a type of immunomodulating agent. Also called aldesleukin and Proleukin.
More Information
Search NCI's Dictionary of Cancer Terms